Molecular Diagnostics for Sexually Transmitted Diseases Market Report 2025

The molecular diagnostics for sexually transmitted diseases market size has grown rapidly in recent years. It will grow from $3.31 billion in 2024 to $3.67 billion in 2025 at a compound annual growth rate (CAGR) of 10.9%. The growth during the historic period can be credited to the rising prevalence of sexually transmitted infections, increased utilization of nucleic acid amplification tests, heightened awareness through government screening initiatives, backing from global health organizations, and early adoption by diagnostic laboratories.

The molecular diagnostics for sexually transmitted diseases market size is expected to see rapid growth in the next few years. It will grow to $5.48 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be ascribed to an increasing emphasis on early disease detection, rising demand for personalized diagnostics, expansion of sexually transmitted infection surveillance initiatives, growing public-private collaborations, and a greater preference for non-invasive testing approaches. Key trends during this period include advancements in molecular assay technologies, innovations in point-of-care diagnostic devices, development of multiplex PCR-based testing panels, progress in portable and automated systems, and the integration of artificial intelligence for result interpretation.

The rising prevalence of sexually transmitted infections (STIs) is expected to drive growth in the molecular diagnostics for sexually transmitted diseases market. STIs are infections caused by bacteria, viruses, or parasites that are transmitted through sexual contact, affecting the reproductive and urinary systems. The increasing prevalence is largely attributed to inconsistent use of protection methods, which facilitates transmission among sexually active individuals. Molecular diagnostics enable early and accurate detection of pathogens, including in asymptomatic cases, allowing timely treatment, reducing disease spread, and improving patient outcomes. For example, according to the National Association of County and City Health Officials (NACCHO), a US-based nonprofit, a total of 3,755 congenital syphilis cases were reported in January 2024, representing a 31% increase between 2021 and 2022. This growing prevalence is therefore propelling the molecular diagnostics for STDs market.

Key companies in this market are focusing on innovations such as rapid point-of-care polymerase chain reaction (PCR) devices to enhance diagnostic speed, accuracy, and accessibility. These portable devices combine sample preparation, amplification, and detection in a single unit, enabling sensitive pathogen detection outside traditional labs. For instance, in March 2025, Visby Medical, a US-based diagnostic technology company, launched the Visby Medical Women’s Sexual Health Test. This single-use, handheld PCR device identifies chlamydia, gonorrhea, and trichomoniasis from vaginal samples in 30 minutes without external instrumentation or cold-chain logistics. Authorized for prescription home use, it represents the first FDA-cleared molecular diagnostic test for multiple STIs usable outside clinical settings, reflecting the trend toward decentralized, accessible testing.

In December 2024, OraSure Technologies, a US-based provider of point-of-care and home diagnostic solutions, acquired Sherlock Biosciences. This acquisition expanded OraSure’s molecular diagnostics portfolio in sexual health by integrating Sherlock’s over-the-counter chlamydia and gonorrhea self-test, which delivers lab-quality results in under 30 minutes using CRISPR- and isothermal amplification-based platforms. Sherlock Biosciences specializes in molecular diagnostics for sexually transmitted infections.

Major players in the molecular diagnostics for sexually transmitted diseases market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Hologic Inc., bioMérieux S.A., QuidelOrtho Corporation, QIAGEN N.V., Cepheid, Sansure Biotech Inc., OraSure Technologies Inc., Meridian Bioscience, Seegene Inc., Visby Medical Inc., Zeesan Biotech, Binx Health Inc., GCC Biotech, GeneProof, and Solone Life Sciences India (P) Ltd.

North America was the largest region in the molecular diagnostics for sexually transmitted diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in molecular diagnostics for sexually transmitted diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the molecular diagnostics for sexually transmitted diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Molecular diagnostics for sexually transmitted diseases (STDs) involve methods that detect the genetic material, DNA or RNA of infectious agents to confirm the presence of pathogens. These techniques are highly accurate and sensitive, allowing detection even in asymptomatic cases. By analyzing the molecular structure of pathogens, these diagnostics ensure reliable identification, supporting faster and more precise diagnosis.

The primary product categories for molecular diagnostics of STDs include instruments and services, consumables, and software. Instruments comprise the diagnostic devices and platforms used for pathogen detection, while services cover laboratory testing, sample processing, and interpretation of diagnostic results provided by healthcare or diagnostic companies. These diagnostics employ various technologies, including laboratory-based testing and point-of-care testing, and are used in a range of applications such as testing for chlamydia trachomatis (CT), neisseria gonorrhoeae (NG), syphilis, gonorrhea, herpes simplex virus (HSV), human papillomavirus (HPV), human immunodeficiency virus (HIV), trichomonas, ureaplasma, mycoplasma, and others.

The molecular diagnostics for sexually transmitted diseases market research report is one of a series of new reports that provides molecular diagnostics for sexually transmitted diseases market statistics, including the molecular diagnostics for sexually transmitted diseases industry global market size, regional shares, competitors with the molecular diagnostics for sexually transmitted diseases market share, detailed molecular diagnostics for sexually transmitted diseases market segments, market trends, and opportunities, and any further data you may need to thrive in the molecular diagnostics for sexually transmitted diseases industry. This molecular diagnostics for sexually transmitted diseases market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The molecular diagnostics for sexually transmitted diseases market consists of revenues earned by entities by providing services such as test development, sample collection, nucleic acid amplification, and point of care diagnostics. The market value includes the value of related goods sold by the service provider or included within the service offering. The molecular diagnostics for sexually transmitted diseases market also includes sales of polymerase chain reaction kits, isothermal nucleic acid amplification kits, clustered regularly interspaced short palindromic repeats-based tests, and instrument-free molecular diagnostic systems. values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.